Weight loss will be hugh when FDA approves.
Just hold on. This could be your retirement.
| Price | 2.02 |
| Price Change Today | -$0.04 (-1.94%) |
| P&P rating | ![]() |
| Zacks Rank | 1 - STRONG BUY |
| Open Price | $2.05 |
| Previous Close | $2.06 |
| Daily Range | $2.01 - $2.06 |
| 52-Week Range | $1.21 - $2.62 |
| Volume | 1,922,689 |
| Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase three clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc. | |





Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Just hold on. This could be your retirement.
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment